(firstQuint)A Study to Evaluate the Safety and Efficacy of FMX103 1.

5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea.

 This is a randomized, multicenter, double-blind, vehicle-controlled, 2 arm study to evaluate the safety and efficacy of FMX103 topical foam containing 1.

5% minocycline compared to vehicle, in the treatment of subjects with moderate-to-severe facial papulopustular rosacea.

 Qualified subjects will be randomized to receive 1 of the following 2 treatments: - FMX103 minocycline foam 1.

5% - Vehicle foam.

 A Study to Evaluate the Safety and Efficacy of FMX103 1.

5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea@highlight

The Primary Objectives of FX2016-11 and FX2016-12 are to determine the efficacy and safety of FMX103 1.

5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

